| 7/15/2008 |
HEMISPHERX BIOPHARMA TO HOST INVESTOR CONFERENCE CALL
ON CHRONIC FATIGUE SYNDROME NDA FILING
Discussion to also address other corporate initiatives
|
| 7/14/2008 |
Hemispherx Biopharma, Inc. Announces Settlement
of All Bioclones/Ribotech Litigation
Discussions in progress for potential future partnership in HIV/AIDS and Hepatitis
|
| 7/8/2008 |
Hemispherx Biopharma’s Ampligen® NDA for Chronic Fatigue Syndrome Accepted for Review by the FDA
Marks the first drug candidate for approval to treat CFS,
and the first compound in the TLR class
|
| 6/16/2008 |
Hemispherx Biopharma, Inc. Announces Settlement of
Arbitration with Laboratorios del Dr. Esteve
Hemispherx regains licensing rights in Spain, Portugal and Andorra
|
| 6/2/2008 |
Hemispherx Biopharma, Inc. Completes Enrollment in Phase II Study
of Ampligen® as Seasonal Flu Vaccine Enhancer
Six-month study will also assess potential cross-protection against H5N1 avian influenza
|
More Releases...
Click Here for a complete archive
Transfer Agent
Continental Stock Transfer & Trust Company
Shareowner Services
2 Broadway
New York, New York 10004
Tel: 212-509-4000
Fax: 212-509-5150
Independent Public Accountants
McGladrey & Pullen, LLP
Number of Shares of Common Stock
As of August 7,
2007 there were
72,826,971 shares of Hemispherx common stock issued and outstanding. If you need additional assistance or information regarding the company, contact Hemispherx Biopharma’s Investor Relations representative.
Investor Relations:
Dianne Will
Phone: 518-398-6222
Fax: 518-398-6369
or send an e-mail to:
ir@hemispherx.net
|
